[Dasatinib. A novel tyrosine kinase inhibitor for the treatment of chronic myeloid leukaemia]
Publikation: Bidrag til tidsskrift › Tidsskriftartikel › Forskning › fagfællebedømt
Chronic myeloid leukaemia is characterized by an abnormal tyrosin kinase in the cytoplasm of the clonal cells. The enzyme is derived from a fusion gene on the Philadelphia-chromosome, evolved by a translocation between chromosomes 9 and 22. Understanding the biology of the tyrosin kinase led to targeted therapy, inhibiting the ATP-binding site by a small molecule--imatinib (Glivec). A novel 2nd generation tyrosin kinase inhibitor--dasatinib (Sprycel)--is now available in cases of insufficient response or intolerance to imatinib
Udgivelsesdato: 2008/1/28
Udgivelsesdato: 2008/1/28
Originalsprog | Dansk |
---|---|
Tidsskrift | Ugeskrift for læger |
Vol/bind | 170 |
Udgave nummer | 5 |
Sider (fra-til) | 331-333 |
Antal sider | 2 |
ISSN | 0041-5782 |
Status | Udgivet - 2008 |
ID: 14146800